Novacea Shares Double on Licensing Deal with Schering-Plough

Biotechnology company Novacea and drug developer Schering-Plough said they signed a licensing agreement for prostate cancer treatment candidate Asentar. Novacea shares jumped as much as $9.19 or 114% to $17.25 before giving back some of the gains .

South San Francisco, Calif.-based Novacea, which is conducting late-stage studies on the drug candidate, will receive an upfront payment of $60 million, including a $35 million reimbursement for past research and development expenses. It will also receive a license fee of $25 million and a commitment from Schering-Plough to buy $12 million in Novacea common stock.

Novacea has the potential to receive pre-commercial milestone payments of up to $380 million and future royalties, the company said.

Schering-Plough will be responsible for all "forward development" costs and will fund commercialization of the drug.


Contact U.S. News


    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • It would be nice to see above 200,000, says Dallas Fed President Richard Fisher, revealing what he hopes to see from Friday's jobs report.

  • Dallas Fed President Richard Fisher, discusses the Lone Star State's economic boom.

  • Things are getting better and if it continues, I personally believe we should move up the date of liftoff, says Dallas Fed President Richard Fisher, sharing his thoughts on tapering the Fed's easy money policy and when he expects to see interest rates increase.